Customer Experience Partner - Immunology/Rare Disease (Fixed Term Contract)

Location: Midrand, South Africa; territory travel required, including approximately 40% travel during a sales cycle.

Company

hirify.global is an R&D-driven, AI-powered biopharma company developing medicines and vaccines based on expertise in the immune system.

What you will do

• Implement sales strategies and tactics for the immunology and rare disease portfolio to achieve sales objectives.
• Develop territory business plans, analyze market and competitor activity, and allocate resources to high-potential customers.
• Build relationships with medical specialists, key stakeholders, opinion leaders, and the rare disease community.
• Deliver approved medico-marketing messages through in-person, virtual, telephone, email, and messaging channels.
• Organize scientific exchange meetings, participate in congresses, and support disease and product awareness initiatives.
• Maintain accurate customer records and submit call, activity, and monthly reports while escalating pharmacovigilance data and product technical complaints.

Requirements

• University degree; a science degree is advantageous.
• More than 5 years of pharmaceutical sales experience, including at least 5 years in specialty care.
• Experience in commercial or medical roles involving biotechnology or highly specialized pharmaceutical products.
• Established relationships with relevant medical specialists and customers in the territory.
• Strong communication, presentation, negotiation, analytical, planning, prioritization, and problem-solving skills.
• Valid driver’s license and willingness to travel approximately 40% in a sales cycle.

Culture & Benefits

• Collaboration with medical, marketing, regulatory, and other cross-functional teams.
• Work in an environment emphasizing integrity, resilience, adaptability, accountability, and continuous learning.
• Participation in hirify.global’s One hirify.global vision and values.
• Equal opportunity employment across diverse backgrounds and identities.